

Conformity with CEN/TS and ISO Standards

Cornelia Stumptner





CEN/TS:

CEN/TC 140 Technical Specifications for molecular in vitro diagnostic examinations — Specifications for pre-examination processes





<u>CEN/TS 16827-1:2015</u> FFPE tissue — RNA

CEN/TS 16827-2:2015 FFPE tissue — Proteins

CEN/TS 16827-3:2015 FFPE tissue — DNA

CEN/TS 16826-1:2015 Frozen tissue — RNA

CEN/TS 16826-2:2015 Frozen tissue — Proteins

CEN/TS 16835-1:2015 Blood — Cellular RNA

CEN/TS 16835-2:2015 Blood — Genomic DNA

CEN/TS 16835-3:2015 Blood — Circul. cell free DNA

CEN/TS 16945:2016 Metabolomics in urine, serum

& plasma





ONR CEN/TS 16827-1

Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for FFPE tissue — Part 1: Isolated RNA (CEN/TS 16827-1:2015)



CEN/TS:

CEN/TC 140 Technical Specifications for molecular in vitro diagnostic examinations – Specifications for pre-examination processes





Target groups

- ✓ In-vitro diagnostic laboratories
- ✓ *In-vitro* diagnostics developers and manufacturers
- ✓ Institutions and commercial organizations performing biomedical research
- ✓ Biobanks
- ✓ Regulation authorities

08.06.2017



CEN/TS:

CEN/TC 140 Technical Specifications for molecular in vitro diagnostic examinations — Specifications for pre-examination processes



Why necessary?

- → 70% decisions in hospital based on diagnostics or lab test results
- → 10% of patients die due to diagnostic errors
- → Pre-analytical phase accounts for 46% to 68% of diagnostic errors
- → This caused ~1.2 Mill US-D in an US mid-sized hospital
- → 28 bill US-D in pharma due to irreproducible pre-clinical results
- → 40-70% of published research findings are not reproducible

N Kaushik et al, 2014; LP Freedman et al, 2015; Economist 2013



CEN/TS:

CEN/TC 140 Technical Specifications for molecular in vitro diagnostic examinations – Specifications for pre-examination processes








Scientific evidence-based






Public & private researchers, standardization & improvement of pre-analytical procedures

ISO/TC212 WG4





ISO/DIS 20166-1 FFPE - RNA

ISO/DIS 20166-2 FFPE - Prot.

ISO/DIS 20166-3 FFPE - DNA, ...

ISO/TC 276 Biotechnology

08.06.2017





Development of 11 new CEN/TS and 2 ISO standards & Raising awareness for and implementation of standards

- 3 Venous whole blood circul. tumor/organ cells RNA, DNA, protein & staining
- 1 Venous whole blood exosomes cfc RNA
- 1 Saliva DNA
- 1 Frozen tissue DNA
- 1 Urine/other body fluids cfcDNA
- 3 fine needle aspirates RNA, DNA, protein
- 1 Saliva & stool DNA
- 1 Saliva DNA
- 1 FFPE tissue in-situ st aining
- 1 Metabolomics urine, plasma, serum

CEN/TS

ISO

1 Scope



This Technical Specification gives recommendations for the handling, documentation and processing of FFPE tissue specimens intended for RNA analysis during the preanalytical phase before a molecular assay is performed. This Technical Specification is applicable to molecular *in vitro* diagnostic examinations (e.g., *in vitro* diagnostic laboratories, laboratory customers, developers and manufacturers of *in vitro* diagnostics, institutions and commercial organizations performing biomedical research, biobanks, and regulatory authorities).

at

The formalin fixation and the paraffin embedding process lead to modifications of the RNA molecules, which can impact the validity and reliability of the analytical test results.

Therefore, it is essential to take special measures to minimize the described profile changes and modifications within the tissue for subsequent RNA analysis.

2 Normative references



The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

EN ISO 15189:2012, Medical laboratories — Requirements for quality and competence (ISO 15189:2012, Corrected version 2014-08-15)

ISO 15190, Medical laboratories — Requirements for safety



3 Terms and definitions

For the purposes of this document, the terms and definitions given in EN ISO 15189:2012 and the following apply.

3.1

ambient temperature

unregulated temperature of the surrounding air

3.2

analytical phase

processes that start with the isolated analyte and include all kinds of parameter testing or chemical

Structure



FFPE Tissue - RNA

Outside the laboratory

Collection of primary tissue

Transport requirements

Inside the laboratory

Primary tissue sample receipt

Fixation of the specimen

Evaluation of the pathology

Processing and paraffin embedding

Storage requirements (paraffin blocks & sections)

Isolation of total RNA

General information (FFPE, PFPE)

Quantity and quality assessment of RNA

Storage of isolated RNA

08.06.2017

Content



FFPE Tissue - RNA	FROZEN-RNA	
Outside the laboratory	Outside the laboratory	
Collection of primary tissue	Collection of tissue	
Transport requirements	Transport requirements	
Inside the laboratory	Inside the laboratory	
Primary tissue sample receipt	Primary tissue sample receipt	
Fixation of the specimen	Evaluation of the pathology	
Evaluation of the pathology	Cryo storage (stabilization)	
Processing and paraffin embedding	Storage requirements (cryo)	
Storage requirements (paraffin blocks & sections)		X SI
Isolation of total RNA	Isolation of total RNA	Self-Assessmen Tool_TISSUE
General information (FFPE, PFPE)	General information (cryo)	
Quantity and quality assessment of RNA	Quantity and quality assessment of	of RNA
Storage of isolated RNA	Storage of isolated RNA	

BBMRI Self-Assessment Took BBMRI.at

		BBMR.at CEN/TS	Self Assessment Tool		F	FPE			
		FFPE-RNA (ONR CEI	ased on: N/TS 16827-1_2015-11-01) EN/TS 16826-1 2015-09-15)			ANCED c Sample Data		V	
		Outside the laboratory			Sample data	3			
		Collection of tissue			FFPE	Source of data			
	1	Information about sample donor		Т	FFPE	Source of data		and the last	
hould		Donor/Patient ID documented	e.g. code	T				Self-Assessment	
hould	1.2.	Health status of donor/patient documented	e.g. healthy, disease type, concomitant disease					_Tool_TISSUE	
hould	1.3.	Medical treatment documented	e.g. anaesthetics, medications, surgical or diagnostic procedures (e.g. biopsy device used for the collection);			Primary ti	ssue collection		
hould	1.4.	Start of warm ischemia documented	Surgery: Date of vessel ligation/arterial clamping time			Informatio	on about the sam	ple donor	
hould			Surgery: Time of vessel ligation/arterial clamping time			Donor/paties	nt ID documented?		○ Yes
	2	Information on the primary tissue sample			FFPE	should	Te lo documentos.		O No (e.g. code)
hall	2.2.	Cold ischemia (start) documented	Date of tissue removal from body			5 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			LANGESTON OF PROPERTY
			Time of tissue removal from body				s of donor/patient do	cumented?	O Yes
hall	2.3.	Tissue type and condition	General tissue type and condition			should			O No
		documented	Organ of origin + location within						(e.g. healthy, disease
hall	2.4.	Type and start of fixation (if started	Date of start			Medical trea	tment prior to tissue	collection	O Yes
		outside the biobank) documented	Time of start			- documented		concedion	O No
			Fixative type Fixation condition	L		should	3		(e.g. anaesthetics, me diagnostic procedures
						Start of isch documented should	emia within the body i?	(warm ischemia)	○ Yes ○ No
			Online SAT "FFPE –	<u>- R</u>	NA" >>	Date of vess ischemia)? should	sel ligation/arterial cla	amping time (warm	O Yes O No
	Online SAT "Frozen			<u>1 –</u>	RNA" >>	Time of vess ischemia)? should	sel ligation/arterial cla	amping time (warm	O Yes O No



Cornelia Stumptner
Medizinische Universität Graz
BBMRI.at Project Manager

Medizinische Universität Graz

8010 Graz Austria

THANK YOU!

BBMRI.at

Neue Stiftingtalstraße 2/B/6 A-8010 Graz Austria www.bbmri.at